Digital Pathology Market worth $1,371 million - Increasing adoption of digital pathology to enhance lab efficiency

MarketsandMarkets™ Research Report's View on Revenue Impact?

The Global Digital Pathology market is projected to reach USD 1,371 million by 2026 from USD 736 million in 2021, at a CAGR of 13.2% during the forecast period.

Factors Responsible for Growth and In-Depth Analysis?

The Digital pathology helps improve lab efficiency by reducing costs, decreasing turnaround times, and providing users with access to subject-matter expertise. Improvements in lab efficiency are critical as patients and physicians are dependent on lab results for diagnostic decisions, and diagnostic tests are required to be completed and reported quickly & accurately. Moreover, access to digital slides via web services eliminate shipping costs and travel time for pathologists. The outbreak of the COVID-19 pandemic has led to the implementation of lockdowns and social distancing restrictions. Such restrictions have increased the demand for digital pathology solutions, as pathologists can use these to view diagnostic results for primary diagnosis remotely.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=844&utm_source=openpr&utm_medium=referral

Leading Key Players and Analysis:

The major players in the global Digital Pathology market include Leica Biosystems (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Visiopharm A/S (Denmark), Aiforia Technologies Oy (Finland), Akoya Biosciences (US), Corista (US), Indica Labs (US), Objective Pathology Services (Canada), Sectra AB (Sweden), OptraSCAN (US), Glencoe Software (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Inspirata, Inc. (US), PathAI (US), Proscia Inc. (US), Kanteron Systems (Spain), Mikroscan Technologies (US), Motic (US), and Paige (US).

Geographical Analysis in Detailed?

North America accounted for the largest share of the digital pathology market in 2020. The increasing prevalence of cancer, rising demand for quality diagnostics, the introduction of favorable reimbursement policies, and the implementation of favorable initiatives by the governments in the US and Canada are major factors driving the growth of the digital pathology market in North America

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=844&utm_source=openpr&utm_medium=referral

Industry Segmentation:

The human pathology segment accounted for the largest share of the Digital Pathology market in 2020

Based on type, the global digital pathology market is segmented into human pathology and veterinary pathology. The human pathology segment accounted for the largest share of the digital pathology market in 2020. This is due to the increasing number of cancer research activities and growing collaborations among research institutes, universities, and pathology laboratories.

The drug discovery, segment accounted for the largest share of the Digital Pathology market in 2020.

Based on application, the digital pathology market is segmented into drug discovery, disease diagnosis, and training & education. The drug discovery segment accounted for the largest share of the digital pathology market in 2020. Growth in R&D expenditure fueled by the need for numerous preclinical and clinical studies performed during the drug discovery and development process is a major factor responsible for market growth.

The pharmaceutical & biotechnology companies, segment accounted for the largest share of the Digital Pathology market in 2020.

Based on end users, the global digital pathology market is segmented into pharmaceutical & biotechnology companies, hospitals & reference laboratories, and academic & research institutes. The pharmaceutical & biotechnology companies segment accounted for the largest share of the digital pathology market in 2020. The large share of this segment can be attributed to the increasing use of digital pathology for drug discovery studies and drug toxicology testing. Biotechnology companies also use digital pathology for biobanking, biopharmaceutical studies, molecular assays, and the development of individualized medicine.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=844&utm_source=openpr&utm_medium=referral

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

This release was published on openPR.